The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
Eisai is starting new trials for BAN2401, just 24 hours after dumping phase 3 trials of aducanumab.
Drug accelerator Cydan is hiring on Yongchang Qiu, Ph.D., as vice president of preclinical development and Ryan Tyler, Ph.D., as senior director of preclinical…
In our EuroBiotech roundup this week, Enterone forms a cancer pact, Motif soars on an FDA update and Affimed receives a Genentech payment.
In this week's EuroBiotech Report, Alexion strikes deals with European biotechs, Nightstar discusses a Biogen deal and Genfit sets IPO terms.
Forma Therapeutics has poached a Genentech senior VP, Frank Lee, to be its new CEO, effective March 27.
The deal will see Alexion pay $25 million upfront to work with Zealand on the subcutaneously delivered therapies.
Benaim's move comes as Rexahn closes in on data from a phase 2a trial of its pancreatic cancer prospect.
Biogen and Eisai are throwing in the towel on late-stage tests for their key Alzheimer’s drug, as experts reveal the drug just won’t make the grade.